helmholtzeyeinstituteРоссийский офтальмологический журналRussian Ophthalmological Journal2072-00762587-5760Real time Publishers10.21516/2072-0076-2022-15-3-146-149helmholtzeyeinstitute-1064Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWSЗначение дислипидемии при первичной открытоугольной глаукомеSignificance of dyslipidemia for primary open-angle glaucomahttps://orcid.org/0000-0001-6041-1264ЭрбК.ErbC.

Карл Эрб — доктор, профессор, директор.

Глазная клиника Виттенбергплац, 23–26, Кляйнштрассе, Берлин, D-10787

Carl Erb — Dr., professor, director.

23–26, Kleiststrasse Berlin, D-10787

КимА.KimA.

Анастасия Ким — докторант, факультет медицины и здравоохранения.

71, проспект аль-Фараби, Алматы, 050049

Anastassiya Kim — PhD student. Faculty of Medicine and Health Care. Faculty of Medicine and Health Care.

71 al-Farabi Ave, Almaty, 050049

anastassiyakim26@gmail.comЧастный институт прикладной офтальмологии Берлина, Глазная клиника ВиттенбергплацГерманияPrivate Institute of Applied Ophthalmology Berlin, c/o Eye clinic WittenbergplatzGermanyКазахский национальный университет имени аль-ФарабиКазахстанAl-Farabi Kazakh National UniversityKazakhstan202224092022153146149Copyright © Эрб К., Ким А., 20222022Эрб К., Ким А.Erb C., Kim A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://roj.igb.ru/jour/article/view/1064

Снижение внутриглазного давления (ВГД) в настоящее время считается основной стратегией остановки или торможения прогрессирования глаукомной нейропатии зрительного нерва. Однако эта цель достигается лишь у 1 из 7 больных первичной открытоугольной глаукомой (ПОУГ). В связи с этим важно определить дополнительные факторы риска, на которые можно воздействовать терапевтически. Одним из таких факторов риска может быть нарушение липидного обмена. Материал и методы. Поиск литературы в PubMed по запросам «первичная открытоугольная глаукома», «дислипидемия» в период с 2000 по 2021 г. Результаты. ПОУГ в настоящее время считается системной нейродегенерацией с нейровоспалением как ключевым фактором. Окисленный липопротеин низкой плотности (ЛПНП) действует как свободный радикал (так называемый биоактивный липид) с провоспалительными свойствами, который способствует глаукоматозному нейровоспалению. Заключение. Помимо целевого персонифицированного снижения ВГД, у каждого пациента с ПОУГ следует скорректировать нарушения липидного обмена, связанные с ЛПНП. Пороговым ориентиром следует считать уровень холестерина ЛПНП в крови ниже 100 мг/дл (2,6 ммоль/л).

Reduction of intraocular pressure is currently considered as the main strategy to stop or slow down the progression of glaucomatous optic neuropathy. However, this goal is achieved in only 1 in 7 patients with primary open-angle glaucoma (POAG). Therefore, it is important to determine further risk factors that can be therapeutically influenced. One example of such risk factors is lipid metabolism disorders. Material and methods. Literature search in PubMed using the queries “primary open-angle glaucoma” and “dyslipidemia” limiting oneself to the period from 2000 to 2021. Results. POAG is currently considered to be a systemic neurodegeneration with neuroinflammation at the forefront. Oxidized low density lipoprotein (oxLDL) acts as a free radical (so-called bioactive lipid) with pro-inflammatory properties and promotes glaucomatous neuroinflammation. Conclusion. In addition to a personalized targeted pressure-oriented intraocular pressure reduction, LDL-associated lipid metabolic disorders should be corrected in every POAG patient. LDL cholesterol below 100 mg/dl (2.6 mmol/l) in the blood is the critical threshold level.

глаукомадислипидемиямитохондриальная патологиянейровоспалениеglaucomadyslipidemiamitochondriopathyneuroinflammationReferencesMaier P.C., Funk J., Schwarzer G., Antes G., Falck-Ytter Y.T. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ. 2005 Jul 16; 331 (7509): 134. doi: 10.1136/bmj.38506.594977.E0Maier P.C., Funk J., Schwarzer G., Antes G., Falck-Ytter Y.T. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ. 2005 Jul 16; 331 (7509): 134. doi: 10.1136/bmj.38506.594977.E0Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. 2002 Jun; 120 (6): 701-13; discussion 829-30. doi: 10.1001/archopht.120.6.701Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. 2002 Jun; 120 (6): 701-13; discussion 829-30. doi: 10.1001/archopht.120.6.701Heijl A., Leske M.C., Bengtsson B., et al.; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 2002 Oct; 120 (10): 1268-79. doi: 10.1001/archopht.120.10.1268Heijl A., Leske M.C., Bengtsson B., et al.; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 2002 Oct; 120 (10): 1268-79. doi: 10.1001/archopht.120.10.1268Chan J.W., Chan N.C.Y., Sadun A.A. Glaucoma as Neurodegeneration in the Brain. Eye Brain. 2021 Jan 18; 13: 21-8. doi: 10.2147/EB.S293765Chan J.W., Chan N.C.Y., Sadun A.A. Glaucoma as Neurodegeneration in the Brain. Eye Brain. 2021 Jan 18; 13: 21-8. doi: 10.2147/EB.S293765Wey S., Amanullah S., Spaeth G.L., et al. Is primary open-angle glaucoma an ocular manifestation of systemic disease? Graefes Arch. Clin. Exp. Ophthalmol. 2019 Apr; 257 (4): 665-73. doi: 10.1007/s00417-019-04239-9Wey S., Amanullah S., Spaeth G.L., et al. Is primary open-angle glaucoma an ocular manifestation of systemic disease? Graefes Arch. Clin. Exp. Ophthalmol. 2019 Apr; 257 (4): 665-73. doi: 10.1007/s00417-019-04239-9Erb C. Sekundare Neuroprotektion beim Glaukom durch erganzende medikamentose Therapiekonzepte. Klin. Monbl. Augenheilkd. 2020; 237 (02): 163-74. doi: 10.1055/a-1093-0945Erb C. Sekundare Neuroprotektion beim Glaukom durch erganzende medikamentose Therapiekonzepte. Klin. Monbl. Augenheilkd. 2020; 237 (02): 163-74. doi: 10.1055/a-1093-0945Erb C., Gast U., Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch. Clin. Exp. Ophthalmol. 2008 Nov; 246 (11): 1593-601. doi: 10.1007/s00417-008-0881-9Erb C., Gast U., Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch. Clin. Exp. Ophthalmol. 2008 Nov; 246 (11): 1593-601. doi: 10.1007/s00417-008-0881-9Lin H.C., Chien C.W., Hu C.C., et al. Comparison of comorbid conditions between open-angle glaucoma patients and a control cohort: a case-control study. Ophthalmology. 2010 Nov; 117 (11): 2088-95. doi: 10.1016/j.ophtha.2010.03.003Lin H.C., Chien C.W., Hu C.C., et al. Comparison of comorbid conditions between open-angle glaucoma patients and a control cohort: a case-control study. Ophthalmology. 2010 Nov; 117 (11): 2088-95. doi: 10.1016/j.ophtha.2010.03.003Touyz R.M., Rios F.J., Alves-Lopes R., et al. Oxidative stress: A unifying paradigm in hypertension. Can. J. Cardiol. 2020 May; 36: 659-70. doi:10.1016/j.cjca.2020.02.081Touyz R.M., Rios F.J., Alves-Lopes R., et al. Oxidative stress: A unifying paradigm in hypertension. Can. J. Cardiol. 2020 May; 36: 659-70. doi:10.1016/j.cjca.2020.02.081Burgos-Morin E, Abad-JimenezZ., Maranon A.M., et al. Relationship between oxidative stress, ER stress, and inflammation in type 2 diabetes: The battle continues. J. Clin. Med. 2019 Sep 4; 8 (9): 1385. doi: 10.3390/jcm8091385Burgos-Morin E, Abad-JimenezZ., Maranon A.M., et al. Relationship between oxidative stress, ER stress, and inflammation in type 2 diabetes: The battle continues. J. Clin. Med. 2019 Sep 4; 8 (9): 1385. doi: 10.3390/jcm8091385Miller Y.I., Shyy J.Y. Context-dependent role of oxidized lipids and lipoproteins in inflammation. Trends Endocrinol. Metab. 2017 Feb; 28 (2): 143-52. doi: 10.1016/j.tem.2016.11.002Miller Y.I., Shyy J.Y. Context-dependent role of oxidized lipids and lipoproteins in inflammation. Trends Endocrinol. Metab. 2017 Feb; 28 (2): 143-52. doi: 10.1016/j.tem.2016.11.002Han C., Rice M.W., Cai D. Neuroinflammatory and autonomic mechanisms in diabetes and hypertension. Am. J. Physiol. Endocrinol. Metab. 2016 Jul 1; 311 (1): E32-41. doi: 10.1152/ajpendo.00012.2016Han C., Rice M.W., Cai D. Neuroinflammatory and autonomic mechanisms in diabetes and hypertension. Am. J. Physiol. Endocrinol. Metab. 2016 Jul 1; 311 (1): E32-41. doi: 10.1152/ajpendo.00012.2016Hacke C., Erb C., Weisser B. Risikofaktoren und Zielwerte in der kardiovaskulären Primär- und Sekundärprävention: Bedeutung für das Glaukom. Klin. Monatsbl. Augenheilkd. 2018 Feb; 235 (02): 151–6. doi:10.1055/s-0044-101260Hacke C., Erb C., Weisser B. Risikofaktoren und Zielwerte in der kardiovaskulären Primär- und Sekundärprävention: Bedeutung für das Glaukom. Klin. Monatsbl. Augenheilkd. 2018 Feb; 235 (02): 151–6. doi:10.1055/s-0044-101260Tsimikas S, Miller Y.I. Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr. Pharm. Des. 2011; 17 (1): 27-37. doi: 10.2174/138161211795049831Tsimikas S, Miller Y.I. Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr. Pharm. Des. 2011; 17 (1): 27-37. doi: 10.2174/138161211795049831Kattoor A.J., Goel A., Mehta J.L. LOX-1: Regulation, signaling and its role in atherosclerosis. Antioxidants (Basel). 2019; 8: 218. Published 2019 Jul 11. doi: 10.3390/antiox8070218Kattoor A.J., Goel A., Mehta J.L. LOX-1: Regulation, signaling and its role in atherosclerosis. Antioxidants (Basel). 2019; 8: 218. Published 2019 Jul 11. doi: 10.3390/antiox8070218Roy Chowdhury S.K., Sangle G.V., Xie X., et al. Effects of extensively oxidized low-density lipoprotein on mitochondrial function and reactive oxygen species in porcine aortic endothelial cells. Am. J. Physiol. Endocrinol. Metab. 2010 Jan; 298 (1): E89-98. doi: 10.1152/ajpendo.00433.2009Roy Chowdhury S.K., Sangle G.V., Xie X., et al. Effects of extensively oxidized low-density lipoprotein on mitochondrial function and reactive oxygen species in porcine aortic endothelial cells. Am. J. Physiol. Endocrinol. Metab. 2010 Jan; 298 (1): E89-98. doi: 10.1152/ajpendo.00433.2009Chang I.L., Elner G., Yue Y.J., et al. Expression of modified low-density lipoprotein receptors by trabecular meshwork cells. Curr Eye Res. 1991 Dec; 10 (12): 1101-12. doi: 10.3109/02713689109024127Chang I.L., Elner G., Yue Y.J., et al. Expression of modified low-density lipoprotein receptors by trabecular meshwork cells. Curr Eye Res. 1991 Dec; 10 (12): 1101-12. doi: 10.3109/02713689109024127Wang T., Ouyang H., Zhou H., et al. Pro-atherogenic activation of A7r5 cells induced by the oxLDL/p2GPI/anti-fJ2GPI complex. Int. J. Mol. Med. 2018 Oct; 42 (4): 1955-66. doi: 10.3892/ijmm.2018.3805Wang T., Ouyang H., Zhou H., et al. Pro-atherogenic activation of A7r5 cells induced by the oxLDL/p2GPI/anti-fJ2GPI complex. Int. J. Mol. Med. 2018 Oct; 42 (4): 1955-66. doi: 10.3892/ijmm.2018.3805Hsieh H.L., Wang H.H., Wu W.B., Chu P.J., Yang C.M. Transforming growth factor-p1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-kB pathways. J. Neuroinflammation. 2010; 7: 88. https://doi.org/10.1186/1742-2094-7-88Hsieh H.L., Wang H.H., Wu W.B., Chu P.J., Yang C.M. Transforming growth factor-p1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-kB pathways. J. Neuroinflammation. 2010; 7: 88. https://doi.org/10.1186/1742-2094-7-88Fleenor D.L., Shepard A.R., Hellberg P.E., et al. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest. Ophthalmol .Vis. Sci. 2006 Jan; 47 (1): 226-34. doi: 10.1167/iovs.05-1060Fleenor D.L., Shepard A.R., Hellberg P.E., et al. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest. Ophthalmol .Vis. Sci. 2006 Jan; 47 (1): 226-34. doi: 10.1167/iovs.05-1060Pertl L., Mossbock G., Wedrich A., et al. Triglycerides and open angle glaucoma — A Meta-analysis with meta-regression. Sci Rep. 2017; 7: 7829. https://doi.org/10.1038/s41598-017-08295-1Pertl L., Mossbock G., Wedrich A., et al. Triglycerides and open angle glaucoma — A Meta-analysis with meta-regression. Sci Rep. 2017; 7: 7829. https://doi.org/10.1038/s41598-017-08295-1Wang Y.X., Tao J.X., Yao Y. The association of intraocular pressure with metabolic syndrome and its components: a Meta-analysis and systematic review. Int J Ophthalmol. 2019; 12: 510-6.Wang Y.X., Tao J.X., Yao Y. The association of intraocular pressure with metabolic syndrome and its components: a Meta-analysis and systematic review. Int J Ophthalmol. 2019; 12: 510-6.Mach F., Baigent C., Catapano A. L., et al. 2019 ESC/EAS Guidelines for the management of dyslipida-emias: lipid modification to reduce cardiovascular risk: The Task Force for the ma-nagement of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. January 2020; 41 (1): 111-88. https://doi.org/10.1093/eurheartj/ehz455Mach F., Baigent C., Catapano A. L., et al. 2019 ESC/EAS Guidelines for the management of dyslipida-emias: lipid modification to reduce cardiovascular risk: The Task Force for the ma-nagement of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. January 2020; 41 (1): 111-88. https://doi.org/10.1093/eurheartj/ehz455Deedwania P., Volkova N. Dyslipidemia and lipid-lowering therapy in the elderly. Expert Rev. Cardiovasc. Ther. 2005 May; 3 (3): 453-63. doi: 10.1586/14779072.3.3.453Deedwania P., Volkova N. Dyslipidemia and lipid-lowering therapy in the elderly. Expert Rev. Cardiovasc. Ther. 2005 May; 3 (3): 453-63. doi: 10.1586/14779072.3.3.453Koushki K., Shahbaz S.K., Mashayekhi K., et al. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin. Rev. Allergy Immunol. 2021 Apr; 60 (2): 175-99. doi: 10.1007/s12016-020-08791-9Koushki K., Shahbaz S.K., Mashayekhi K., et al. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin. Rev. Allergy Immunol. 2021 Apr; 60 (2): 175-99. doi: 10.1007/s12016-020-08791-9Newman C.B., Preiss D., Tobert J.A., et al. Statin safety and associated adverse events: A scientific statement from the American Heart Association [published correction appears in. Arterioscler Thromb. Vasc. Biol. 2019 Feb; 39 (2): e38-e81. doi: 10.1161/ATV.0000000000000073Newman C.B., Preiss D., Tobert J.A., et al. Statin safety and associated adverse events: A scientific statement from the American Heart Association [published correction appears in. Arterioscler Thromb. Vasc. Biol. 2019 Feb; 39 (2): e38-e81. doi: 10.1161/ATV.0000000000000073Stein J.D., Newman-Casey P.A., Talwar N., et al. The relationship between statin use and open-angle glaucoma. Ophthalmology. 2012 Oct; 119 (10): 2074-81. doi: 10.1016/j.ophtha.2012.04.029Stein J.D., Newman-Casey P.A., Talwar N., et al. The relationship between statin use and open-angle glaucoma. Ophthalmology. 2012 Oct; 119 (10): 2074-81. doi: 10.1016/j.ophtha.2012.04.029Thiermeier N., Lammer R., Mardin C., Hohberger B. Erlanger Glaucoma Registry: Effect of a long-term therapy with statins and acetyl salicylic acid on glaucoma conversion and progression. Biology (Basel). 2021 Jun 16; 10 (6): 538. doi: 10.3390/biology10060538Thiermeier N., Lammer R., Mardin C., Hohberger B. Erlanger Glaucoma Registry: Effect of a long-term therapy with statins and acetyl salicylic acid on glaucoma conversion and progression. Biology (Basel). 2021 Jun 16; 10 (6): 538. doi: 10.3390/biology10060538Oesterle A., Liao J.K. The pleiotropic effects of statins — from coronary artery disease and stroke to atrial fibrillation and ventricular tachyarrhythmia. Curr. Vasc. Pharmacol. 2019; 17(3): 222-32. doi: 10.2174/1570161116666180817155058Oesterle A., Liao J.K. The pleiotropic effects of statins — from coronary artery disease and stroke to atrial fibrillation and ventricular tachyarrhythmia. Curr. Vasc. Pharmacol. 2019; 17(3): 222-32. doi: 10.2174/1570161116666180817155058Kosowski M., Smolarczyk-Kosowska J., Hachula M., et al. The effects of statins on neurotransmission and their neuroprotective role in neurological and psychiatric disorders. Molecules. 2021 May 11; 26 (10): 2838. doi: 10.3390/molecules26102838Kosowski M., Smolarczyk-Kosowska J., Hachula M., et al. The effects of statins on neurotransmission and their neuroprotective role in neurological and psychiatric disorders. Molecules. 2021 May 11; 26 (10): 2838. doi: 10.3390/molecules26102838Pierzchlinska A., Drozdzik M., Bialecka M. A possible role for HMG-CoA reductase inhibitors and its association with HMGCR genetic variation in Parkinson's disease. Int. J. Mol. Sci. 2021 Nov 11; 22 (22): 12198. doi: 10.3390/ijms222212198Pierzchlinska A., Drozdzik M., Bialecka M. A possible role for HMG-CoA reductase inhibitors and its association with HMGCR genetic variation in Parkinson's disease. Int. J. Mol. Sci. 2021 Nov 11; 22 (22): 12198. doi: 10.3390/ijms222212198Bhat A., Dalvi H., Jain H., et al. Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal. Curr. Res. Pharmacol. Drug Discov. 2020 Dec 31; 2: 100012. doi: 10.1016/j.crphar.2020.100012Bhat A., Dalvi H., Jain H., et al. Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal. Curr. Res. Pharmacol. Drug Discov. 2020 Dec 31; 2: 100012. doi: 10.1016/j.crphar.2020.100012Kim M.L., Sung K.R., Kwon J., Choi G.W., Shin J.A. Neuroprotective effect of statins in a rat model of chronic ocular hypertension. Int. J. Mol. Sci. 2021 Nov 19; 22 (22): 12500. doi: 10.3390/ijms222212500Kim M.L., Sung K.R., Kwon J., Choi G.W., Shin J.A. Neuroprotective effect of statins in a rat model of chronic ocular hypertension. Int. J. Mol. Sci. 2021 Nov 19; 22 (22): 12500. doi: 10.3390/ijms222212500Coleman A.L., Diehl D.L., Jampel H.D., Bachorik P.S., Quigley H.A. Topical timolol decreases plasma high-density lipoprotein cholesterol level. Arch. Ophthalmol. 1990 Sep; 108 (9): 1260-3. doi: 10.1001/archopht.1990.01070110076028Coleman A.L., Diehl D.L., Jampel H.D., Bachorik P.S., Quigley H.A. Topical timolol decreases plasma high-density lipoprotein cholesterol level. Arch. Ophthalmol. 1990 Sep; 108 (9): 1260-3. doi: 10.1001/archopht.1990.01070110076028Yamamoto T., Kitazawa Y., Noma A., et al. The effects of the beta-adrenergic-blocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients. J. Glaucoma. 1996 Aug; 5 (4): 252-7. PMID: 8795770Yamamoto T., Kitazawa Y., Noma A., et al. The effects of the beta-adrenergic-blocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients. J. Glaucoma. 1996 Aug; 5 (4): 252-7. PMID: 8795770Cheng Y.W., Chiu M.J., Chen Y.F., et al. The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer's disease. Alzheimers Res. Ther. 2020 Aug 4; 12 (1): 91. doi: 10.1186/s13195-020-00658-7Cheng Y.W., Chiu M.J., Chen Y.F., et al. The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer's disease. Alzheimers Res. Ther. 2020 Aug 4; 12 (1): 91. doi: 10.1186/s13195-020-00658-7Saiz-Vazquez O., Puente-Martinez A., Ubillos-Landa S., Pacheco-Bonrostro J., Santabarbara J. Cholesterol and Alzheimer's Disease risk: A Meta-Meta-Analysis. Brain Sci. 2020 Jun 18; 10 (6): 386. doi: 10.3390/brainsci10060386Saiz-Vazquez O., Puente-Martinez A., Ubillos-Landa S., Pacheco-Bonrostro J., Santabarbara J. Cholesterol and Alzheimer's Disease risk: A Meta-Meta-Analysis. Brain Sci. 2020 Jun 18; 10 (6): 386. doi: 10.3390/brainsci10060386

The authors declare that there are no conflicts of interest present.